Use este identificador para citar ou linkar para este item: http://hdl.handle.net/11690/1899
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorCavalcanti, Alexandre B.-
dc.contributor.authorZampieri, Fernando G.-
dc.contributor.authorRosa, Regis G.-
dc.contributor.authorAzevedo, Luciano C. P.-
dc.contributor.authorVeiga, Viviane C.-
dc.contributor.authorAvezum, Alvaro-
dc.contributor.authorDamiani, Lucas P.-
dc.contributor.authorMarcadenti, Aline-
dc.contributor.authorKawano-Dourado, Letícia-
dc.contributor.authorLisboa, Thiago-
dc.contributor.authorJunqueira, Debora L. M.-
dc.contributor.authorSilva, Pedro G. M. de Barros E-
dc.contributor.authorTramujas, Lucas-
dc.contributor.authorAbreu-Silva, Erlon O.-
dc.contributor.authorLaranjeira, Ligia N.-
dc.contributor.authorSoares, Aline T.-
dc.contributor.authorEchenique, Leandro S.-
dc.contributor.authorPereira, Adriano J.-
dc.contributor.authorFreitas, Flávio G. R.-
dc.contributor.authorGebara, Otávio C. E.-
dc.contributor.authorDantas, Vicente C. S.-
dc.contributor.authorFurtado, Remo H. M.-
dc.contributor.authorMilan, Eveline P.-
dc.contributor.authorGolin, Nicole A.-
dc.contributor.authorCardoso, Fábio F.-
dc.contributor.authorMaia, Israel S.-
dc.contributor.authorHoffmann Filho, Conrado R.-
dc.contributor.authorKormann, Adrian P. M.-
dc.contributor.authorAmazonas, Roberto B.-
dc.contributor.authorOliveira, Monalisa F. Bocchi de-
dc.contributor.authorSerpa-Neto, Ary-
dc.contributor.authorFalavigna, Maicon-
dc.contributor.authorLopes, Renato D.-
dc.contributor.authorMachado, Flávia R.-
dc.contributor.authorBerwanger, Otavio-
dc.date.accessioned2021-07-30T17:29:03Z-
dc.date.available2021-07-30T17:29:03Z-
dc.date.issued2020-
dc.identifier.citationCAVALCANTI, A. B. et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N. Engl. J. Med., v. 383, n. 21, p. 2041-2052, nov., 2020. Disponível em: https://www.nejm.org/doi/10.1056/NEJMoa2019014?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Acesso e: 22 jul. 2021.pt_BR
dc.identifier.urihttp://hdl.handle.net/11690/1899-
dc.description.abstractBACKGROUND Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed. RESULTS A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P=1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P=1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. CONCLUSIONS Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.)pt_BR
dc.language.isoen_USpt_BR
dc.publisherMassachusetts Medical Societypt_BR
dc.rightsOpen Accessen
dc.subjectHydroxychloroquinept_BR
dc.subjectAzithromycinpt_BR
dc.subjectMild-to-Moderate Covid-19pt_BR
dc.titleHydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19pt_BR
dc.typeArtigopt_BR
Aparece nas coleções:Artigo de Periódico (PPGSDH)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Hydroxychloroquine with or without Azithromycin_NEJM.pdfOpen Access642,49 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.